| 摘要 |
<p>The invention consists in the use of bioactive products derived from dairy proteins - lactoferrin - and the hydrolyzate of lactoferrin that contains said products. This involves a peptide with fifteen amino acid residues (called LfcinB 17-31), and another that is a reduced version thereof (called LfcinB20-25), which are derived from bovine lactoferrin, as effective inhibitors of the angiotensin converting enzyme (ACE). The peptides that are the subject of the patent may be obtained chemically, enzymatically or biotechnologically and give rise to peptides with in vitro and/or ex vivo angiotensin converting enzyme inhibitory activity measured as the reduction in the contraction of rabbit carotid arteries induced by exposure to angiotensin 1. These nutraceutical products, possibly in the form of bioactive peptides, are useful both in the food industry and in the pharmaceutical industry.</p> |
